ClinicalTrials.gg
CompletedNCT02854436GalahadUpdated Dec 22, 2025Results posted

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

A Phase 2 interventional study of Niraparib in Prostatic Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 110 sites in 15 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
289
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing niraparib in Prostatic Neoplasms — 3 open to participants now, 7 under way, 2 of them phase 3. niraparib · Prostatic Neoplasms.

Enrollment
4th of 19
289 · median 34
Started
2016
with 2 others
Phase 2
8 of 19
2 open now
Registered
3rd of 19
by date
Lead sponsor
4 of 19
Janssen Research & Development, LLC

Among the 19 studies testing niraparib in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2016, is one of 8 in phase 2, and was the 3rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 19 studies testing niraparib in Prostatic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing niraparib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.

Read the detailed description

This is a multicenter and open-label (participants and researchers are aware of the treatment that participants are receiving) study that consists of 4 phases: a Prescreening Phase for biomarker evaluation only, a Screening Phase, a Treatment Phase (Cycle 1 Day 1 and will continue until the study drug is discontinued), a Follow-up Phase (every 3 months after end of treatment visit), and a Long-term Extension Phase (until participants no longer derive benefit from treatment or until further notification on different means of study treatment). Participants will be monitored for safety during the study period, and up to 30 days after the last dose of study drug.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Prostate cancer
  • CRPC
  • Metastatic castrate-resistant prostate cancer
  • Prostate neoplasm
  • Galahad
  • Niraparib
  • DNA anomalies
  • DNA defect
  • PARP inhibitor
  • PARPi
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is excluded)
  • Received a taxane-based chemotherapy for the treatment of prostate cancer with evidence of disease progression on or after treatment, or discontinued from a taxane-based chemotherapy due to an adverse event
  • Received a second-generation or later androgen receptor (AR)-targeted therapy (for example, abiraterone acetate plus prednisone, enzalutamide, apalutamide) for the treatment of metastatic prostate cancer with evidence of disease progression or non-metastatic castration-resistant prostate cancer with evidence of subsequent metastasis
  • Biomarker-positive by at least one of the following criteria: (a) Biallelic deoxyribonucleic acid (DNA)-repair anomaly based on a sponsor validated blood or tissue assay; (b) Germline pathogenic Breast Cancer gene (BRCA) 1 or BRCA2 by any test (somatic local results must be confirmed as positive by the sponsor-validated assay before dosing)
  • Progression of metastatic prostate cancer in the setting of castrate levels of testosterone or history of bilateral orchiectomy at study entry

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor
  • Prior platinum-based chemotherapy for the treatment of prostate cancer
  • Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
  • Symptomatic or impending cord compression
  • Symptomatic
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
289 participants (actual)

Study arms

  • Experimental
    Niraparib

    Participants will receive 300 milligram (mg) niraparib (3 capsules\*100 mg) orally once daily.

    Drug: Niraparib

Interventions

  • Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.

    Also known as: JNJ-64091742

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation

    ORR defined as percentage of participants with BRCA DNA-repair anomalies and measurable disease whose best response is either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and with no evidence of bone progression per Prostate Cancer Working Group 3 (PCWG3) criteria.

    Time frame: Up to 52 months

Secondary outcomes

  1. Objective Response Rate for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Non-Breast Cancer Gene (BRCA) Mutation

    ORR defined as percentage of participants with BRCA deoxyribonucleic acid (DNA)-repair anomalies and measurable disease whose best response is either CR or PR per RECIST 1.1 and with no evidence of bone progression per PCWG3 criteria.

    Time frame: Up to 52 months

  2. Circulating Tumor Cells (CTC) Response Rate

    CTC response rate was defined as the percentage of participants with CTC equals to (=) 0 per 7.5 milliliter (mL) blood at 8 weeks post-baseline in participants with baseline CTC greater than (\>) 0.

    Time frame: At 8 weeks post-baseline

  3. Overall Survival (OS)

    OS is defined as time from enrollment to death from any cause.

    Time frame: Up to 52 months

  4. Radiographic Progression-Free Survival (rPFS)

    rPFS was defined as time from enrollment to radiographic progression or death from any cause, whichever occurred first. Radiographic progression was evaluated per RECIST 1.1 criteria for soft tissue disease and per PCWG3 criteria for bone disease.

    Time frame: Up to 52 months

  5. Time to Radiographic Progression

    Time to radiographic progression is defined as time from enrollment to radiographic progression or death due to disease progression, whichever occurs first. Disease progression is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

    Time frame: Up to 52 months

  6. Time to Prostate-Specific Antigen (PSA) Progression

    Time to PSA progression was defined as time from enrollment to the first date of documented PSA progression based on PCWG3 criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanograms per milliliter (ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks.

    Time frame: Up to 52 months

  7. Time to Symptomatic Skeletal Event (SSE)

    Time to SSE was defined as the time from enrollment to first occurrence of one of the following symptomatic skeletal events: tumor-related spinal cord compression, radiation to bone to relieve skeletal symptoms, surgery to bone or need for tumor-related orthopedic surgical intervention, symptomatic or pathologic fracture.

    Time frame: Up to 52 months

  8. Duration of Objective Response

    Duration of objective response is defined as time from CR or PR to radiographic progression of disease, unequivocal clinical progression or death, whichever occurs first. Unequivocal clinical progression defined as one or more of following: 1) deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS) to Grade 3 or higher; 2) need to initiate any of following because of tumor progression (even in absence of radiographic evidence of disease): alternative anticancer therapy for prostate cancer, radiation therapy, surgical interventions for complications due to tumor progression.

    Time frame: Up to 52 months

  9. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

    Time frame: Up to 52 months

  10. Number of Participants With Worst Toxicity Grades for Clinical Laboratory Tests Based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE)

    Number of participants with worst toxicity grades for clinical laboratory tests (chemistry and hematology) based on NCI-CTCAE were reported. The chemistry laboratory parameters were: alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased and the hematology parameters were: hemoglobin increased, lymphocyte count increased. Grading was done as: Grade 1 (=mild), Grade 2 (=moderate), Grade 3 (=severe) and Grade 4 (=potentially life-threatening).

    Time frame: Up to 52 months

07

Results

Posted Mar 8, 2022

Participant flow

Participant flow — Overall Study
MilestoneNiraparib
Started289
Intent to treat participants (breast cancer gene [brca] and non-brca participants)223
Completed0
Not completed289
Withdrew: Adverse event1
Withdrew: Death208
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject24
Withdrew: Other45
Withdrew: Physician decision6

Outcome measures

PrimaryObjective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation

ORR defined as percentage of participants with BRCA DNA-repair anomalies and measurable disease whose best response is either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and with no evidence of bone progression per Prostate Cancer Working Group 3 (PCWG3) criteria.

Time frame:
Up to 52 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation
percentage of participantsNiraparib
Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation34.2 (23.7 to 46.0)
SecondaryObjective Response Rate for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Non-Breast Cancer Gene (BRCA) Mutation

ORR defined as percentage of participants with BRCA deoxyribonucleic acid (DNA)-repair anomalies and measurable disease whose best response is either CR or PR per RECIST 1.1 and with no evidence of bone progression per PCWG3 criteria.

Time frame:
Up to 52 months
Reported as:
Number · percentage of participants
Objective Response Rate for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Non-Breast Cancer Gene (BRCA) Mutation
percentage of participantsNiraparib
Objective Response Rate for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Non-Breast Cancer Gene (BRCA) Mutation10.6 (3.5 to 23.1)
SecondaryCirculating Tumor Cells (CTC) Response Rate

CTC response rate was defined as the percentage of participants with CTC equals to (=) 0 per 7.5 milliliter (mL) blood at 8 weeks post-baseline in participants with baseline CTC greater than (\>) 0.

Time frame:
At 8 weeks post-baseline
Reported as:
Number · percentage of participants
Circulating Tumor Cells (CTC) Response Rate
percentage of participantsNiraparib
BRCA23.7
Non-BRCA8.5
SecondaryOverall Survival (OS)

OS is defined as time from enrollment to death from any cause.

Time frame:
Up to 52 months
Reported as:
Median · months
Overall Survival (OS)
monthsNiraparib
BRCA13.01 (11.04 to 14.29)
Non-BRCA9.63 (8.05 to 13.44)
SecondaryRadiographic Progression-Free Survival (rPFS)

rPFS was defined as time from enrollment to radiographic progression or death from any cause, whichever occurred first. Radiographic progression was evaluated per RECIST 1.1 criteria for soft tissue disease and per PCWG3 criteria for bone disease.

Time frame:
Up to 52 months
Reported as:
Median · months
Radiographic Progression-Free Survival (rPFS)
monthsNiraparib
BRCA8.08 (5.55 to 8.38)
Non-BRCA3.71 (1.97 to 5.49)
SecondaryTime to Radiographic Progression

Time to radiographic progression is defined as time from enrollment to radiographic progression or death due to disease progression, whichever occurs first. Disease progression is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

Time frame:
Up to 52 months
Reported as:
Median · months
Time to Radiographic Progression
monthsNiraparib
BRCA8.08 (5.75 to 8.97)
Non-BRCA3.78 (2.00 to 5.55)
SecondaryTime to Prostate-Specific Antigen (PSA) Progression

Time to PSA progression was defined as time from enrollment to the first date of documented PSA progression based on PCWG3 criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanograms per milliliter (ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks.

Time frame:
Up to 52 months
Reported as:
Median · months
Time to Prostate-Specific Antigen (PSA) Progression
monthsNiraparib
BRCA5.13 (4.60 to 5.59)
Non-BRCA3.65 (2.83 to 3.71)
SecondaryTime to Symptomatic Skeletal Event (SSE)

Time to SSE was defined as the time from enrollment to first occurrence of one of the following symptomatic skeletal events: tumor-related spinal cord compression, radiation to bone to relieve skeletal symptoms, surgery to bone or need for tumor-related orthopedic surgical intervention, symptomatic or pathologic fracture.

Time frame:
Up to 52 months
Reported as:
Median · months
Time to Symptomatic Skeletal Event (SSE)
monthsNiraparib
BRCA13.80 (10.41 to NA)
Non-BRCA10.35 (8.18 to NA)
SecondaryDuration of Objective Response

Duration of objective response is defined as time from CR or PR to radiographic progression of disease, unequivocal clinical progression or death, whichever occurs first. Unequivocal clinical progression defined as one or more of following: 1) deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS) to Grade 3 or higher; 2) need to initiate any of following because of tumor progression (even in absence of radiographic evidence of disease): alternative anticancer therapy for prostate cancer, radiation therapy, surgical interventions for complications due to tumor progression.

Time frame:
Up to 52 months
Reported as:
Median · months
Duration of Objective Response
monthsNiraparib
BRCA5.55 (3.91 to 7.20)
non-BRCA5.16 (2.14 to NA)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

Time frame:
Up to 52 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsNiraparib
Number of Participants With Adverse Events (AEs)288
SecondaryNumber of Participants With Worst Toxicity Grades for Clinical Laboratory Tests Based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE)

Number of participants with worst toxicity grades for clinical laboratory tests (chemistry and hematology) based on NCI-CTCAE were reported. The chemistry laboratory parameters were: alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased and the hematology parameters were: hemoglobin increased, lymphocyte count increased. Grading was done as: Grade 1 (=mild), Grade 2 (=moderate), Grade 3 (=severe) and Grade 4 (=potentially life-threatening).

Time frame:
Up to 52 months
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grades for Clinical Laboratory Tests Based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE)
ParticipantsNiraparib
ALT increased (Grade 1 or 2)67
ALT increased (Grade 3 or 4)4
Alkaline phosphatase increased (Grade 1 or 2)102
Alkaline phosphatase increased (Grade 3 or 4)7
AST increased (Grade 1 or 2)70
AST increased (Grade 3 or 4)4
Blood bilirubin increased (Grade 1 or 2)9
Blood bilirubin increased (Grade 3 or 4)2
Creatinine increased (Grade 1 or 2)45
Creatinine increased (Grade 3 or 4)2
GGT increased (Grade 1 or 2)105
GGT increased (Grade 3 or 4)14
Hemoglobin increased (Grade 1 or 2)0
Hemoglobin increased (Grade 3 or 4)0
Lymphocyte count increased (Grade 1 or 2)6
Lymphocyte count increased (Grade 3 or 4)0

Adverse events

Collected over Up to 52 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niraparib208/289 (72%)134/289 (46.4%)280/289 (96.9%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventNiraparib
ThrombocytopeniaBlood and lymphatic system disorders17/289
AnaemiaBlood and lymphatic system disorders13/289
General Physical Health DeteriorationGeneral disorders8/289
VomitingGastrointestinal disorders7/289
Back PainMusculoskeletal and connective tissue disorders7/289
HeadacheNervous system disorders6/289
Spinal Cord CompressionNervous system disorders6/289
HaematuriaRenal and urinary disorders6/289
ConstipationGastrointestinal disorders5/289
NauseaGastrointestinal disorders5/289
Most frequent other events
Showing 10 of 37
Most frequent other events
EventNiraparib
NauseaGastrointestinal disorders167/289
AnaemiaBlood and lymphatic system disorders154/289
VomitingGastrointestinal disorders109/289
FatigueGeneral disorders105/289
ConstipationGastrointestinal disorders98/289
ThrombocytopeniaBlood and lymphatic system disorders94/289
Decreased AppetiteMetabolism and nutrition disorders93/289
Back PainMusculoskeletal and connective tissue disorders59/289
NeutropeniaBlood and lymphatic system disorders54/289
Weight DecreasedInvestigations50/289

Baseline characteristics

Age, Continuous
Age, Continuous(years)Niraparib
Mean68.8 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Niraparib
Female0
Male289
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Niraparib
American Indian or Alaska Native0
Asian16
Black or African American9
Native Hawaiian or Other Pacific Islander0
White205
More than one race3
Unknown or Not Reported51
Other5
Region of Enrollment
Region of Enrollment(Participants)Niraparib
AUSTRALIA31
BELGIUM18
BRAZIL12
CANADA21
DENMARK1
FRANCE48
ISRAEL6
NETHERLANDS6
RUSSIAN FEDERATION7
SOUTH KOREA5
SPAIN39
SWEDEN24
TAIWAN9
UNITED KINGDOM17
UNITED STATES45
08

Study locations

110 sites
  • Tucson, Arizona, United States
  • Los Angeles, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • Evanston, Illinois, United States
  • Danville, Kentucky, United States
  • Louisville, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Omaha, Nebraska, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Lancaster, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Myrtle Beach, South Carolina, United States
  • Houston, Texas, United States
  • Charlottesville, Virginia, United States
  • Fairfax, Virginia, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
  • Camperdown, Australia
  • Darlinghurst, Australia
  • East Albury, Australia
  • Kurralta Park, Australia
  • Macquarie University, Australia
  • Melbourne, Australia
  • Murdoch, Australia
  • Port Macquarie, Australia
  • Randwick, Australia
  • Wahroonga, Australia
  • Aalst, Belgium
  • Brussels, Belgium
  • Charleroi, Belgium
  • Ghent, Belgium
  • Haine-Saint-Paul, Belgium
  • Hasselt, Belgium
  • Kortrijk, Belgium
  • Liège, Belgium
  • Namur, Belgium
  • Ottignies, Belgium
  • Wilrijk, Belgium
  • Barretos, Brazil
  • Belo Horizonte, Brazil
  • Curitiba, Brazil
  • Fortaleza, Brazil
  • Ijuí, Brazil
  • Itajaí, Brazil
  • Joinville, Brazil
  • Natal, Brazil
  • Salvador, Brazil
  • São Paulo, Brazil
  • Vancouver, British Columbia, Canada
  • Oshawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Québec, Quebec, Canada
  • Aarhus N, Denmark
  • Copenhagen N, Denmark
  • Herlev, Denmark
  • Odense C, Denmark
  • Avignon, France
  • Besançon, France
  • Caen, France
  • Lyon, France
  • Nice, France
  • Paris, France
  • Reims, France
  • Strasbourg, France
  • Villejuif, France
  • Beersheba, Israel
  • Haifa, Israel
  • Kfar Saba, Israel
  • Ramat Gan, Israel
  • Zrifin, Israel
  • Alkmaar, Netherlands
  • Amsterdam, Netherlands
  • Groningen, Netherlands
  • Maastricht, Netherlands
  • Rotterdam, Netherlands
  • Moscow, Russia
  • Omsk, Russia
  • Tomsk, Russia
  • Seoul, South Korea
  • Barcelona, Spain
  • Córdoba, Spain
  • Madrid, Spain
  • Málaga, Spain
  • Pozuelo de Alarcón, Spain
  • Santander, Spain
  • Santiago de Compostela, Spain
  • Seville, Spain
  • Valencia, Spain
  • Gothenburg, Sweden
  • Lund, Sweden
  • Stockholm, Sweden
  • Umeå, Sweden
  • Kaohsiung City, Taiwan

Showing the first 100 of 110 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Smith MR, Sandhu S, George DJ, Chi KN, Saad F, Thiery-Vuillemin A, Stahl O, Olmos D, Danila DC, Gafanov R, Castro E, Moon H, Joshua AM, Mason GE, Espina BM, Liu Y, Lopez-Gitlitz A, Francis P, Bevans KB, Fizazi K. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. J Manag Care Spec Pharm. 2023 Jul;29(7):758-768. doi: 10.18553/jmcp.2023.29.7.758. PubMed 37404070 ↗
  • Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Stahl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. PubMed 35131040 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jan 2021, 52 months.

Results were first posted in Mar 2022, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 52 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2016
First posted
Aug 3, 2016
StartActual
Aug 31, 2016
Primary completionActual
Jan 26, 2021
CompletionActual
Aug 16, 2023
Results first posted
Mar 8, 2022
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02854436
Responsible party
Sponsor
First posted
Aug 3, 2016
Start date
Aug 31, 2016
Primary completion
Jan 26, 2021
Completion
Aug 16, 2023
Results posted
Mar 8, 2022
Last update
Dec 22, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion